Emergent BioSolutions (EBS) Stock Forecast, Price Target & Predictions
EBS Stock Forecast
Emergent BioSolutions stock forecast is as follows: an average price target of $51.50 (represents a 648.55% upside from EBS’s last price of $6.88) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
EBS Price Target
The average price target for Emergent BioSolutions (EBS) is $51.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $38.00. This represents a potential 648.55% upside from EBS's last price of $6.88.
EBS Analyst Ratings
According to 3 Wall Street analysts, Emergent BioSolutions's rating consensus is 'Buy'. The analyst rating breakdown for EBS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Emergent BioSolutions Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 04, 2022 | - | Wells Fargo | $38.00 | $33.06 | 14.94% | 452.33% |
| Apr 29, 2022 | - | Chardan Capital | $65.00 | $33.98 | 91.29% | 844.77% |
The latest Emergent BioSolutions stock forecast, released on May 04, 2022 by Wells Fargo company, set a price target of $38.00, which represents a 14.94% increase from the stock price at the time of the forecast ($33.06), and a 452.33% increase from EBS last price ($6.88).
Emergent BioSolutions Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.88 | $6.88 | $6.88 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Emergent BioSolutions stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Emergent BioSolutions's last price of $6.88. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 22, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Aug 16, 2024 | Benchmark | Buy | Buy | Hold |
| Aug 16, 2024 | Benchmark Co. | Underperform | Underperform | Hold |
| Jun 24, 2024 | Benchmark Co. | Underperform | Underperform | Hold |
| Jun 20, 2024 | Benchmark | Buy | Buy | Hold |
| Mar 07, 2024 | Benchmark | Positive | Buy | Upgrade |
| Apr 10, 2023 | Benchmark | Hold | Positive | Upgrade |
| Nov 10, 2022 | Benchmark | - | Hold | Downgrade |
| Apr 29, 2022 | Chardan Capital | Buy | Buy | Hold |
Emergent BioSolutions's last stock rating was published by Rodman & Renshaw on Aug 22, 2024. The company Initialise its EBS rating from "null" to "Buy".
Emergent BioSolutions Financial Forecast
Emergent BioSolutions Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $270.50M | $337.90M | $165.10M | $330.70M | $240.00M | $242.70M | $307.50M | $723.20M | $329.00M | $397.50M | $343.00M | $583.00M | $385.20M | $394.70M | $192.50M | $360.30M | $311.80M | $243.20M | $190.60M | $270.73M | $173.65M | $220.20M | $117.81M | $193.81M | $149.43M |
| Avg Forecast | $267.00M | $271.00M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $234.64M | $183.12M | $181.10M | $863.87M | $183.32M | $121.78M |
| High Forecast | $267.00M | $271.00M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $281.56M | $219.75M | $217.32M | $1.04B | $219.99M | $146.14M |
| Low Forecast | $267.00M | $271.00M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $187.71M | $146.50M | $144.88M | $691.09M | $146.66M | $97.42M |
| # Analysts | 1 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 9 | 17 | 8 | 18 | 20 |
| Surprise % | - | - | - | - | - | 1.14% | 1.56% | 1.03% | 1.11% | 0.89% | 0.90% | 1.08% | 1.08% | 0.68% | 1.00% | 0.96% | 1.02% | 0.88% | 1.34% | 0.97% | 1.01% | 1.08% | 1.15% | 0.95% | 1.15% | 0.95% | 1.22% | 0.14% | 1.06% | 1.23% |
Emergent BioSolutions's average Quarter revenue forecast for Dec 23 based on 2 analysts is $293.41M, with a low forecast of $293.41M, and a high forecast of $293.41M. EBS's average Quarter revenue forecast represents a 8.47% increase compared to the company's last Quarter revenue of $270.50M (Sep 23).
Emergent BioSolutions EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 9 | 17 | 8 | 18 | 20 |
| EBITDA | - | - | - | - | - | $-11.00M | $-292.90M | $-108.60M | $-16.10M | $-23.10M | $-30.50M | $35.30M | $305.70M | $-4.40M | $49.00M | $122.40M | $290.40M | $91.40M | $155.70M | $15.50M | $108.50M | $96.90M | $22.90M | $-1.60M | $36.65M | $34.59M | $79.17M | $3.18M | $65.48M | $58.11M |
| Avg Forecast | $41.42M | $42.04M | $29.48M | $34.76M | $45.52M | $36.84M | $33.54M | $27.48M | $46.10M | $-10.91M | $42.03M | $21.72M | $289.23M | $-8.62M | $80.16M | $77.59M | $246.70M | $88.38M | $141.96M | $15.50M | $118.53M | $63.52M | $29.64M | $-4.96M | $31.01M | $36.38M | $62.08M | $6.12M | $61.74M | $44.91M |
| High Forecast | $41.42M | $42.04M | $29.48M | $41.71M | $45.52M | $36.84M | $33.54M | $32.98M | $46.10M | $-8.73M | $42.03M | $26.07M | $347.08M | $-6.90M | $96.19M | $93.11M | $296.04M | $106.06M | $170.35M | $18.60M | $142.24M | $76.23M | $35.56M | $-3.97M | $37.22M | $43.66M | $74.49M | $7.35M | $74.09M | $53.89M |
| Low Forecast | $41.42M | $42.04M | $29.48M | $27.81M | $45.52M | $36.84M | $33.54M | $21.98M | $46.10M | $-13.09M | $42.03M | $17.38M | $231.39M | $-10.35M | $64.13M | $62.07M | $197.36M | $70.71M | $113.57M | $12.40M | $94.83M | $50.82M | $23.71M | $-5.95M | $24.81M | $29.11M | $49.66M | $4.90M | $49.39M | $35.93M |
| Surprise % | - | - | - | - | - | -0.30% | -8.73% | -3.95% | -0.35% | 2.12% | -0.73% | 1.63% | 1.06% | 0.51% | 0.61% | 1.58% | 1.18% | 1.03% | 1.10% | 1.00% | 0.92% | 1.53% | 0.77% | 0.32% | 1.18% | 0.95% | 1.28% | 0.52% | 1.06% | 1.29% |
0 analysts predict EBS's average Quarter EBITDA for Jun 22 to be $42.03M, with a high of $42.03M and a low of $42.03M. This is 19.08% upper than Emergent BioSolutions's previous annual EBITDA (Mar 22) of $35.30M.
Emergent BioSolutions Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 9 | 17 | 8 | 18 | 20 |
| Net Income | - | - | - | - | - | $-265.90M | $-261.30M | $-183.00M | $-88.00M | $-75.70M | $-56.40M | $-3.70M | $189.30M | $-32.70M | $4.60M | $69.70M | $185.40M | $39.50M | $92.70M | $-12.50M | $46.90M | $43.20M | $-9.50M | $-26.00M | $-3.48M | $20.95M | $50.14M | $-4.91M | $33.94M | $33.55M |
| Avg Forecast | $-9.99M | $-4.73M | $-59.70M | $-3.64M | $-9.99M | $-11.75M | $-34.01M | $-2.88M | $2.31M | $-81.06M | $19.84M | $-2.28M | $179.10M | $-64.08M | $7.53M | $44.18M | $157.50M | $38.20M | $84.52M | $-12.50M | $51.24M | $28.32M | $-12.29M | $-80.60M | $-2.95M | $22.03M | $39.32M | $-9.44M | $32.00M | $25.93M |
| High Forecast | $-9.99M | $-4.73M | $-59.70M | $-2.91M | $-9.99M | $-11.75M | $-34.01M | $-2.30M | $2.31M | $-64.85M | $19.84M | $-1.82M | $214.92M | $-51.26M | $9.03M | $53.02M | $189.00M | $45.83M | $101.42M | $-10.00M | $61.49M | $33.98M | $-9.84M | $-64.48M | $-2.36M | $26.43M | $47.18M | $-7.55M | $38.40M | $31.12M |
| Low Forecast | $-9.99M | $-4.73M | $-59.70M | $-4.37M | $-9.99M | $-11.75M | $-34.01M | $-3.46M | $2.31M | $-97.27M | $19.84M | $-2.73M | $143.28M | $-76.89M | $6.02M | $35.35M | $126.00M | $30.56M | $67.62M | $-15.00M | $40.99M | $22.66M | $-14.75M | $-96.72M | $-3.53M | $17.62M | $31.45M | $-11.32M | $25.60M | $20.75M |
| Surprise % | - | - | - | - | - | 22.64% | 7.68% | 63.53% | -38.02% | 0.93% | -2.84% | 1.63% | 1.06% | 0.51% | 0.61% | 1.58% | 1.18% | 1.03% | 1.10% | 1.00% | 0.92% | 1.53% | 0.77% | 0.32% | 1.18% | 0.95% | 1.28% | 0.52% | 1.06% | 1.29% |
Emergent BioSolutions's average Quarter net income forecast for Mar 22 is $-2.28M, with a range of $-2.73M to $-1.82M. EBS's average Quarter net income forecast represents a -101.20% decrease compared to the company's last Quarter net income of $189.30M (Dec 21).
Emergent BioSolutions SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 9 | 17 | 8 | 18 | 20 |
| SG&A | - | - | - | - | - | $86.00M | $91.40M | $100.50M | $94.20M | $80.20M | $81.10M | $84.80M | $94.20M | $82.10M | $91.20M | $80.90M | $82.10M | $75.50M | $76.00M | $69.70M | $72.20M | $65.00M | $70.80M | $65.40M | $80.69M | $42.10M | $39.51M | $40.20M | $41.98M | $34.50M |
| Avg Forecast | $68.36M | $69.38M | $48.65M | $83.51M | $75.12M | $60.79M | $55.35M | $66.01M | $76.09M | $203.52M | $69.37M | $52.18M | $89.13M | $160.88M | $149.20M | $51.28M | $69.75M | $73.01M | $69.29M | $69.70M | $78.88M | $42.61M | $91.62M | $51.50M | $68.27M | $44.28M | $30.98M | $77.30M | $39.58M | $26.67M |
| High Forecast | $68.36M | $69.38M | $48.65M | $100.21M | $75.12M | $60.79M | $55.35M | $79.22M | $76.09M | $244.22M | $69.37M | $62.62M | $106.95M | $193.06M | $179.03M | $61.54M | $83.70M | $87.61M | $83.15M | $83.64M | $94.65M | $51.13M | $109.95M | $51.50M | $81.93M | $53.14M | $37.17M | $92.76M | $47.49M | $32.00M |
| Low Forecast | $68.36M | $69.38M | $48.65M | $66.81M | $75.12M | $60.79M | $55.35M | $52.81M | $76.09M | $162.81M | $69.37M | $41.75M | $71.30M | $128.71M | $119.36M | $41.03M | $55.80M | $58.41M | $55.44M | $55.76M | $63.10M | $34.09M | $73.30M | $51.50M | $54.62M | $35.43M | $24.78M | $61.84M | $31.66M | $21.33M |
| Surprise % | - | - | - | - | - | 1.41% | 1.65% | 1.52% | 1.24% | 0.39% | 1.17% | 1.63% | 1.06% | 0.51% | 0.61% | 1.58% | 1.18% | 1.03% | 1.10% | 1.00% | 0.92% | 1.53% | 0.77% | 1.27% | 1.18% | 0.95% | 1.28% | 0.52% | 1.06% | 1.29% |
Emergent BioSolutions's average Quarter SG&A projection for Dec 23 is $75.12M, based on 2 Wall Street analysts, with a range of $75.12M to $75.12M. The forecast indicates a -12.65% fall compared to EBS last annual SG&A of $86.00M (Sep 23).
Emergent BioSolutions EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 9 | 17 | 8 | 18 | 20 |
| EPS | - | - | - | - | - | $-5.13 | $-5.15 | $-3.65 | $-1.76 | $-1.52 | $-1.13 | $-0.07 | $3.54 | $-0.61 | $0.09 | $1.31 | $3.51 | $0.75 | $1.76 | $-0.24 | $0.91 | $0.84 | $-0.18 | $-0.51 | $-0.07 | $0.42 | $1.00 | $-0.10 | $0.77 | $0.81 |
| Avg Forecast | $-0.19 | $-0.09 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.55 | $0.61 | $0.69 | $0.42 | $0.66 | $0.32 |
| High Forecast | $-0.19 | $-0.09 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.66 | $0.73 | $0.83 | $0.51 | $0.79 | $0.38 |
| Low Forecast | $-0.19 | $-0.09 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.44 | $0.49 | $0.55 | $0.34 | $0.53 | $0.25 |
| Surprise % | - | - | - | - | - | 22.97% | 7.96% | 2.82% | -40.00% | 24.65% | -2.97% | -0.58% | 0.84% | -0.26% | 0.06% | 1.14% | 1.10% | 0.35% | 2.58% | -24.00% | 0.52% | 0.94% | -1.08% | -5.41% | -0.13% | 0.69% | 1.45% | -0.24% | 1.17% | 2.53% |
According to 0 Wall Street analysts, Emergent BioSolutions's projected average Quarter EPS for Mar 22 is $0.13, with a low estimate of $0.13 and a high estimate of $0.13. This represents a -96.47% decrease compared to EBS previous annual EPS of $3.54 (Dec 21).
Emergent BioSolutions Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | $6.88 | $51.50 | 648.55% | Buy |
| LFCR | Lifecore Biomedical | $5.08 | $8.00 | 57.48% | Buy |
| BHC | Bausch Health Companies | $7.18 | $10.20 | 42.06% | Hold |
| ALKS | Alkermes | $27.74 | $35.50 | 27.97% | Buy |
| ITCI | Intra-Cellular Therapies | $75.11 | $94.00 | 25.15% | Buy |
| NBIX | Neurocrine Biosciences | $122.31 | $146.60 | 19.86% | Buy |
| ZTS | Zoetis | $195.71 | $227.71 | 16.35% | Buy |
| PBH | Prestige Consumer Healthcare | $73.55 | $82.00 | 11.49% | Buy |
| COLL | Collegium Pharmaceutical | $37.38 | $41.50 | 11.02% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PETQ | PetIQ | $30.76 | $31.00 | 0.78% | Buy |
EBS Forecast FAQ
Is Emergent BioSolutions a good buy?
Yes, according to 3 Wall Street analysts, Emergent BioSolutions (EBS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of EBS's total ratings.
What is EBS's price target?
Emergent BioSolutions (EBS) average price target is $51.5 with a range of $38 to $65, implying a 648.55% from its last price of $6.88. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Emergent BioSolutions stock go up soon?
According to Wall Street analysts' prediction for EBS stock, the company can go up by 648.55% (from the last price of $6.88 to the average price target of $51.5), up by 844.77% based on the highest stock price target, and up by 452.33% based on the lowest stock price target.
Can Emergent BioSolutions stock reach $10?
EBS's average twelve months analyst stock price target of $51.5 supports the claim that Emergent BioSolutions can reach $10 in the near future.
What are Emergent BioSolutions's analysts' financial forecasts?
EBS's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $948.25M (high $948.25M, low $948.25M), average EBITDA is $147.7M (high $154.66M, low $140.75M), average net income is $-78.073M (high $-77.344M, low $-78.801M), average SG&A $269.9M (high $286.6M, low $253.2M), and average EPS is $-2.395 (high $-2.395, low $-2.395).
Did the EBS's actual financial results beat the analysts' financial forecasts?
Based on Emergent BioSolutions's last annual report (Dec 2023), the company's revenue was $1.05B, beating the average analysts forecast of $906.74M by 15.72%. Apple's EBITDA was $-726M, missing the average prediction of $143.37M by -606.66%. The company's net income was $-760M, beating the average estimation of $-58.629M by 1197.13%. Apple's SG&A was $368.4M, beating the average forecast of $257.27M by 43.19%. Lastly, the company's EPS was $-14.85, beating the average prediction of $-2.354 by 530.88%. In terms of the last quarterly report (Sep 2023), Emergent BioSolutions's revenue was $270.5M, beating the average analysts' forecast of $237.43M by 13.93%. The company's EBITDA was $-11M, missing the average prediction of $36.84M by -129.86%. Emergent BioSolutions's net income was $-266M, beating the average estimation of $-11.747M by 2163.53%. The company's SG&A was $86M, beating the average forecast of $60.79M by 41.47%. Lastly, the company's EPS was $-5.13, beating the average prediction of $-0.223 by 2197.05%